Home > Focus Areas > Breast Cancer Connect > Post
  • Saved

4yr
Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data - PubMed

Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35552450/

doi: 10.1093/oncolo/oyac075. Online ahead of print. 1 University Hospitals/Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA. 2 Fox Chase Cancer Center, Temple University, Philadelphia, PA, USA. Free article Background: Metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor-2 negative (Her2-) breast cancer remains a significant cause of cancer-related mortality.


Conclusion: While prospective data are needed, analysis of real-world data suggests a survival benefit for continuation of a CDK4/6i beyond frontline progression for patients with HR /Her2− MBC.

  • 4yr
    I would not. Those who got chemotherapy probably had reasons to do so. I had used a different CK4/6 in 3d line and had 2-4 months PFS.
    I would consider these data generally misleading
  • 4yr
    What are your thoughts about continuing CDK4/6i therapy despite a paucity of data? Are you comfortable with this strategy? Please explain.
  • 4yr
    What a great example of the use of real-world data to complement the data that is available in clinical trials. It's an important question to which we don't currently have an answer. RWE studies certainly have their limitations, but they can provide data when prospective data is lacking. Certainly another question is whether there is benefit to CDK4/6i switching (especially from palbo/ribo to abema or vice versa).
  • 4yr
    this is very important issue; also molecular differences

Show More Comments